Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of USANA Health Sciences, Inc. (NYSE:USNA - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 32,269 shares of the company's stock, valued at approximately $870,000. Connor Clark & Lunn Investment Management Ltd. owned about 0.17% of USANA Health Sciences at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Geode Capital Management LLC boosted its stake in shares of USANA Health Sciences by 1.6% in the 4th quarter. Geode Capital Management LLC now owns 301,949 shares of the company's stock worth $10,839,000 after buying an additional 4,829 shares during the last quarter. Wells Fargo & Company MN raised its holdings in USANA Health Sciences by 35.4% during the fourth quarter. Wells Fargo & Company MN now owns 7,961 shares of the company's stock valued at $286,000 after acquiring an additional 2,082 shares during the period. Invesco Ltd. raised its holdings in USANA Health Sciences by 21.9% during the fourth quarter. Invesco Ltd. now owns 116,388 shares of the company's stock valued at $4,177,000 after acquiring an additional 20,882 shares during the period. Barclays PLC increased its holdings in shares of USANA Health Sciences by 12.0% in the fourth quarter. Barclays PLC now owns 31,067 shares of the company's stock worth $1,116,000 after purchasing an additional 3,330 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in USANA Health Sciences during the fourth quarter worth approximately $231,000. Institutional investors own 54.25% of the company's stock.
Wall Street Analysts Forecast Growth
Separately, Wall Street Zen upgraded USANA Health Sciences from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Two equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $36.00.
Check Out Our Latest Research Report on USANA Health Sciences
USANA Health Sciences Stock Performance
USNA stock traded up $1.5610 during midday trading on Friday, reaching $32.1910. The stock had a trading volume of 25,811 shares, compared to its average volume of 175,842. The stock has a market cap of $588.13 million, a PE ratio of 17.86, a P/E/G ratio of 0.99 and a beta of 0.61. The firm has a fifty day simple moving average of $30.95 and a two-hundred day simple moving average of $29.55. USANA Health Sciences, Inc. has a 52-week low of $23.10 and a 52-week high of $41.83.
USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The company reported $0.74 earnings per share for the quarter, topping the consensus estimate of $0.54 by $0.20. The company had revenue of $235.85 million for the quarter, compared to the consensus estimate of $225.20 million. USANA Health Sciences had a return on equity of 9.48% and a net margin of 3.79%. USANA Health Sciences has set its FY 2025 guidance at 2.350-3.000 EPS. On average, sell-side analysts predict that USANA Health Sciences, Inc. will post 2.45 EPS for the current fiscal year.
Insider Buying and Selling
In related news, insider David Mulham Mulham sold 3,515 shares of USANA Health Sciences stock in a transaction dated Wednesday, July 30th. The stock was sold at an average price of $30.26, for a total value of $106,363.90. Following the sale, the insider directly owned 9,260 shares in the company, valued at approximately $280,207.60. The trade was a 27.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Gilbert A. Fuller sold 1,058 shares of USANA Health Sciences stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $29.10, for a total value of $30,787.80. The disclosure for this sale can be found here. In the last three months, insiders have sold 11,364 shares of company stock worth $342,536. Insiders own 0.63% of the company's stock.
About USANA Health Sciences
(
Free Report)
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Recommended Stories
Before you consider USANA Health Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and USANA Health Sciences wasn't on the list.
While USANA Health Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
